Development and Multiple Validation of the Protein Multi-marker Panel for Diagnosis of Pancreatic Cancer
- 27 January 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (8), 2236-2245
- https://doi.org/10.1158/1078-0432.ccr-20-3929
Abstract
Purpose: To develop and validate a protein-based, multi-marker panel that provides superior pancreatic ductal adenocarcinoma (PDAC) detection abilities with sufficient diagnostic performance. Experimental Design: A total of 959 plasma samples from patients at multiple medical centers were used. To construct an optimal, diagnostic, multi-marker panel, we applied data preprocessing procedure to biomarker candidates. The multi-marker panel was developed using a training set comprised of 261 PDAC cases and 290 controls. Subsequent evaluations were performed in a validation set comprised of 65 PDAC cases and 72 controls. Further validation was performed in an independent set comprised of 75 PDAC cases and 47 controls. Results: A multi-marker panel containing 14 proteins was developed. The multi-marker panel achieved areas under the curve (AUCs) of 0.977 and 0.953 for the training set and validation set, respectively. In an independent validation set, the multi-marker panel yielded an AUC of 0.928. The diagnostic performance of the multi-marker panel showed significant improvements compared with carbohydrate antigen (CA) 19-9 alone (training set AUC = 0.977 vs. 0.872, P < 0.001; validation set AUC = 0.953 vs. 0.832, P < 0.01; independent validation AUC = 0.928 vs. 0.771, P < 0.001). When the multi-marker panel and CA 19-9 were combined, the diagnostic performance of the combined panel was improved for all sets. Conclusions: This multi-marker panel and the combined panel showed statistically significant improvements in diagnostic performance compared with CA 19-9 alone and has the potential to complement CA19-9 as a diagnostic marker in clinical practice.Other Versions
Funding Information
- Industrial Strategic Technology Development Program (10079271, 20000134)
- Ministry of Trade, Industry and Energy Korea Health Industry Development Institute (HI14C2640, HL19C0020)
This publication has 47 references indexed in Scilit:
- iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performanceBritish Journal of Cancer, 2013
- Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2013
- pROC: an open-source package for R and S+ to analyze and compare ROC curvesBMC Bioinformatics, 2011
- Cancer Biomarkers: Can We Turn Recent Failures into Success?JNCI Journal of the National Cancer Institute, 2010
- Perspectives of targeted mass spectrometry for protein biomarker verificationCurrent Opinion in Chemical Biology, 2009
- Full Dynamic Range Proteome Analysis of S. cerevisiae by Targeted ProteomicsCell, 2009
- Identification of pancreatic cancer invasion-related proteins by proteomic analysisProteome Science, 2009
- Quantification of Thyroglobulin, a Low-Abundance Serum Protein, by Immunoaffinity Peptide Enrichment and Tandem Mass SpectrometryClinical Chemistry, 2008
- Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancerEuropean Journal of Surgical Oncology, 2007
- Protein biomarker discovery and validation: the long and uncertain path to clinical utilityNature Biotechnology, 2006